Mednet Logo
HomePediatric Hematology/Oncology
Pediatric Hematology/Oncology

Pediatric Hematology/Oncology

Clinical discussions on pediatric blood disorders, childhood cancers, and specialized treatment protocols.

Recent Discussions

How do you advise patients with sickle cell disease on contraception?

1 Answers

Mednet Member
Mednet Member
Hematology · Dana-Farber Cancer Institute

According to both the "ASH Pocket Guidelines" and the National Heart Lung and Blood Guidelines for health maintenance in Women with sickle cell disease, progestin only and barrier methods of contraception are the preferred recommendations for contraception. Combined hormonal agents can be considered...

How do you approach the management of GVHD prophylaxis in the setting of severe infection?

1 Answers

Mednet Member
Mednet Member
Medical Oncology · University of Maryland Cancer Center

GVHD prophylaxis the 1st ~ 3 months after alloSCT is paramount and immunosuppression withdrawal might cause GVHD which can in turn exacerbate or cause infection given the need of corticosteroids to control it. Having said that, case-by-case management is important. As an example, alloSCT using a PTC...

How would you approach management of bleeding risk and factor VIII replacement in a patient with severe hemophilia A undergoing stem cell transplant?

1 Answers

Mednet Member
Mednet Member
Pediatric Hematology/Oncology · Georgetown University Hospital

Same way as anyone with severe hemophilia: Prophy with QOD factor or weekly hemlibra Extra correction for procedures, trauma, or bleeding

What are your top takeaways from ASH 2022?

2
8 Answers

Mednet Member
Mednet Member
Hematology · Hospital of the University of Pennsylvania

1. Late Breaking Abstract (LBA-1): Consolidation Therapy with Blinatumomab Improves Overall Survival in Newly Diagnosed Adult Patients with B-Lineage Acute Lymphoblastic Leukemia in Measurable Residual Disease Negative Remission: Results from the ECOG-ACRIN E1910 Randomized Phase III National Cooper...

How do you approach low to moderate titer of APLS when working up unprovoked DVT if it is persistent on repeat testing?

4
4 Answers

Mednet Member
Mednet Member
Hematology · University of Pittsburgh

I have a low threshold to recommend long term (indefinite) anticoagulation for unprovoked thrombosis, regardless of whether there is positive APLS testing. I do agree with Dr. @Dr. First Last, however, that shared decision-making is important when committing a patient to prolonged anticoagulation, a...

Are there any possible scenarios where you would do phlebotomies for heterozygous hemochromatosis?

1 Answers

Mednet Member
Mednet Member
Hematology · Georgetown University School of Medicine

The answer is yes but unusual. Occasionally, a heterozygote or double heterozygote will be weakly phenotypically positive. If the ferritin and TSAT (on overnight fasting sample) are high, I will. I prefer that blood donation be used but if not an option, I will take it. The iron parameters must be...

How do you approach hormone replacement therapy for premenopausal patients following pelvic radiation therapy?

2
1 Answers

Mednet Member
Mednet Member
Obstetrics & Gynecology · Dana-Farber Cancer Institute

Most patients who undergo pelvic radiation will become menopausal. Physiologically, the outcome is similar to surgical menopause because sufficient doses of radiation result in complete loss of ovarian function. In contrast, after natural menopause, the ovaries continue some types of endocrine funct...

What is the role of local control +/- whole lung irradiation in a patient with relapsed/refractory Ewing sarcoma to the hilum plus multiple lung nodules?

1
2 Answers

Mednet Member
Mednet Member
Radiation Oncology · The Ohio State University - James Cancer Hospital and Solove Research Institute

I would boost residual thoracic disease to at least the usual Ewings gross disease dose of 55.8 (total, including WLI dose). Doses in this range are well known to be safe in the thorax and this multiply relapsed disease is likely to be more treatment refractory than primary disease. SBRT boost seems...

How should elevated PT of unclear etiology and significance be evaluated?

2 Answers

Mednet Member
Mednet Member
Hematology · Mayo Clinic

Mild prolongation of the prothrombin time (PT) may represent a normal ‘outlier’. If there is no obvious explanation for a moderate to marked prolongation of the PT (for example, anticoagulation therapy effect, liver disease, nutritional deficiency like vitamin K deficiency. then the next step is to ...

How would you approach a low to moderate titer of one of the APLS antibodies in a patient with a strong family history but no personal history of thrombosis?

2 Answers

Mednet Member
Mednet Member
Rheumatology · UTMB Health

I would repeat these tests in about 12 weeks or so. Certain infections can transiently induce positive antiphospholipid antibodies, usually non-pathogenic, with certain exceptions.